Andrea Berry, DO
Addiction Medicine · Concord, NHNPI 1669796546
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 51.7% of the total. 2025 is the largest year on record at $111, 4.2 times the $27 reported in 2019.
Across 18 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$191
- Boehringer Ingelheim$45
- Novo Nordisk$30
- Dexcom, Inc.$29
- Amarin Pharma, Inc.$21
- Gilead$19
- plus $34 from 2 others
What the payments were for
- Food & beverage$368100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $191 |
| Boehringer Ingelheim | 2 | $45 |
| Novo Nordisk | 2 | $30 |
| Dexcom, Inc. | 2 | $29 |
| Amarin Pharma, Inc. | 1 | $21 |
| Gilead | 1 | $19 |
| Alkermes, Inc. | 1 | $17 |
| AstraZeneca | 1 | $17 |
How this compares
Too few addiction medicine providers in New Hampshireto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 55 | $5,029 |
| Advair DiskusFluticasone Propion/Salmeterol | 11 | $2,089 |
| Atorvastatin Calcium | 128 | $1,243 |
| Gabapentin | 61 | $661 |
| Ketoconazole | 15 | $629 |
| Lisinopril | 39 | $539 |
| Sertraline Hcl | 23 | $404 |
| Diclofenac Sodium | 13 | $399 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $299 |
| Trazodone Hcl | 15 | $220 |
| Amlodipine Besylate | 32 | $218 |
| Diltiazem Hcl | 35 | $204 |
| Levothyroxine Sodium | 24 | $188 |
| Omeprazole | 21 | $185 |
| Ondansetron Hcl | 12 | $175 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Concord
- Bertrand ColeSomersworth$3K
- Boris GolosarskyNashua$666
- Michael KittayNashua$451
- Lawrence EpsteinSomersworth$317
- Roland LavalleeManchester$221
- Dawn HarlandKeene$51
- Audrey KernSomersworth$13
- Herb MeyerDanville$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.